| May 7, 2026 | management_change | Shareholders elected eleven directors and approved an incentive plan, increasing share reserve by 20 million shares. |
|---|
| Apr 29, 2026 | debt_offering | Danaher issued €3 billion in Floating Rate, 3.250%, 3.625%, and 4.000% Senior Notes to fund the Masimo acquisition. |
|---|
| Apr 21, 2026 | earnings | Danaher reported Q1 2026 net earnings of $1.0 billion ($1.45 EPS) and revenues of $6.0 billion, up 3.5%. |
|---|
| Apr 21, 2026 | Guidance: adjusted_diluted_eps | 8.35 to 8.55 |
|---|
| Apr 21, 2026 | Guidance: adjusted_operating_profit_margin_non_gaap | 26.50 to 26.50 |
|---|
| Apr 21, 2026 | Guidance: average_adjusted_diluted_shares | 714.00 to 714.00 |
|---|
| Apr 21, 2026 | mda_quarterly | Danaher reported a 3.5% increase in total revenues to $5.95 billion for Q1 2026, with core sales growing 0.5%, primarily boosted by a 3.0% favorable currency impact. Net earnings rose to $1.0 billion, or $1.45 diluted EPS, driven by increased core sales and lower net interest expense, while operating profit margin expanded to 22.6%. The Biotechnology segment led growth with 7.0% core sales increase, fueled by bioprocessing consumables demand from large pharma, particularly in Western Europe and China, despite lower equipment sales. Life Sciences saw 0.5% core sales growth, with consumables and filtration business strength, especially in China, offsetting decreased equipment demand and muted academic spending. Conversely, the Diagnostics segment experienced a 4.0% core sales decline, mainly due to decreased demand for respiratory tests and impacts from China's volume-based procurement and healthcare reimbursement changes, leading to a 140 basis point drop in its operating profit margin. Danaher entered an agreement to acquire Masimo Corporation for approximately $9.9 billion, a specialty diagnostics provider, which will be financed by cash on hand and debt, including a new $5.0 billion 364-day credit facility. Operating cash flow increased to $1.32 billion. Geopolitical instability in the Middle East and uncertainty surrounding new U.S. tariffs pose ongoing risks. |
|---|
| Feb 24, 2026 | business | DHR operates in the global life sciences, diagnostics, and biotechnology sectors, providing equipment, consumables, software, and services for healthcare, research, and biopharmaceutical manufacturing. Its Biotechnology segment supports the development and production of biological medicines, including monoclonal antibodies, vaccines, and cell/gene therapies. The Life Sciences segment offers tools for studying biological components like DNA and proteins, aiding drug discovery, and provides filtration solutions. The Diagnostics segment supplies clinical instruments and consumables for disease diagnosis and treatment decisions in various healthcare settings.
Globally diversified, 59% of DHR's 2025 sales were outside the U.S., with a focus on high-growth markets like China (11% of sales). Growth is driven by continuous innovation, R&D, and strategic acquisitions, such as the pending Masimo Corporation acquisition. DHR faces intense competition, rapid technological changes, and evolving customer demands for digital and sustainable solutions. Significant challenges include stringent healthcare regulations (e.g., PAMA, Inflation Reduction Act, China's volume-based procurement) impacting pricing and reimbursement, global economic uncertainties, and operational complexities like supply chain disruptions, cybersecurity, and intellectual property protection. Talent retention and AI integration are also critical for competitiveness. |
|---|
